The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster

Drugs and Aging

Volumn 20, Issue 8, 2003, Pages 561-570

  Lilie, H Martina ^a,b   Wassilew, Sawko W ^a  

^a Klinikum Krefeld   (Germany)

^b Klinikum Krefeld   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACETYLSALICYLIC ACID; ACICLOVIR; AMITRIPTYLINE; ANALGESIC AGENT; ANTIVIRUS AGENT; BUPRENORPHINE; CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; DICLOFENAC; DIPYRONE; FAMCICLOVIR; GABAPENTIN; MORPHINE; NALOXONE; NAPROXEN; PARACETAMOL; PREDNISOLONE; TILIDINE; TRAMADOL; VALACICLOVIR;

CLINICAL TRIAL; CRANIAL NERVE; DISEASE DURATION; DRUG EFFICACY; HERPES ZOSTER; HUMAN; INCIDENCE; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; SPINAL NERVE; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION;

2-AMINOPURINE; ACYCLOVIR; AGE FACTORS; AGED; ANALGESICS; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; DRUG THERAPY, COMBINATION; HERPES ZOSTER; HUMANS; NEURALGIA; PAIN MEASUREMENT; VALINE;

EID: 0038729452     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320080-00002     Document Type: Review

References (51)

1. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25: 571-5
2. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61 (5): 310-6
3. Ghatak NR, Zimmerman HM. Spinal ganglion in herpes zoster. Arch Pathol 1973; 95: 411-5
4. McKendall RR, Klawans HL. Nervous system complications of varicella-zoster virus. In: Vinken PJ, Brujn GW, editors. Handbook of clinical neurology, 34. Amsterdam: Elsevier/North Holland Biomedical Press, 1978: 161-83
5. Dworkin RH, Portenoy RL. Pain and its persistence in Herpes zoster. Pain 1996; 67: 241-51
6. Dworkin RH, Carrington D, Cunningham A, et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res 1997; 33: 73-85
7. Wood MJ, the Herpes Zoster Clinical Trial Consensus Group. How should zoster trials be conducted? J Antimicrob Chemother 1995; 36: 1089-101
8. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-7
9. Shukla S, Gibb A, Fiddian AP. Significant covariates in outcome of herpes zoster rash and pain. Poster 2nd International Conference on the varicella-zoster virus, VZV Research Foundation; 1994 Jul 7-8; Paris
10. Watson CPN. Postherpetic neuralgia in varicella-zoster virus: molecular biology, pathogenesis and clinical aspects. Contrib Microbiol 1999; 3: 128-40
11. Wutzler P, Meister W. Herpes zoster: Symptomatologie, demographische Daten und prognostische Faktoren. Deutsches Aerzteblatt 1997; 17: 1129-33
12. Dworkin RH, Boon RJ, Friffin DR, et al. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl. 1: 76-80
13. Meister W, Neiß A. A scoring system for the risk of postherpetic neuralgia (PHN) [poster]. 3rd International Conference on the Varicella Zoster Virus, VZV Research Foundation; 1997 Mar 9-11; Palm Beach (FL)
14. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster. Arch Fam Med 2000; 9: 863-9
15. Tyring S, Barbarash RA, Nahlikk JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 89-96
16. Crooks RJ, Jones DA, Fiddian AP. Zoster associated chronic pain: an overview of clinical trial with acyclovir. Scand J Infect Suppl 1991; 80: 62-8
17. IHMF Management Strategies Workshop Management. Strategies in herpes: reducing the burden of zoster associated pain update. UK: Parexel MMS Europe Ltd, 1996
18. Johnson RW, Mandal BK. Guidelines for the management of shingles report of a working group of the British Society for the Study of Infection (BSSI). J Infect 1995; 30: 193-200
19. Sklar SH, Blue WT, Alexander EJ, et al. Herpes zoster: the treatment and prevention of neuralgia with adenosine monophosphate. JAMA 1985; 253: 1427-30
20. Wildenhoff KE, Esmann V, Ipsen J, et al. Treatment of trigeminal and thoracic zoster with idoxuridine. Scand J Infect Dis 1981; 13: 257-62
21. Whitley RJ, Weiss H, Gnann Jr JW, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. Ann Intern Med 1996; 125: 376-83
22. Wood MJ, Johnson RW, McKendrick MW, et al. A randomised trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900
23. McKendrick MW, Care C, Burke C, et al. Oral acyclovir in herpes zoster. J Antimicrob Chemother 1984; 14: 661-5
24. van den Broek PJ, van der Meet JW, Mulder JD, et al. Limited value to acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study. Infection 1984; 12: 338-41
25. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1547-53
26. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res. In press
27. Wassilew SW, Schumacher K, Staedtler G, et al. Brivudin compared to famciclovir in the prevention of postherpetic neuralgia: a randomised, double-blind multicenter trial. Presented at the 4th International Conference on varicella, herpes zoster and postherpetic neuralgia; 2001 Mar 3-5; La Jolla (CA), 2001
28. Whitley RJ. Approaches to the treatment of varicella-zoster virus infections in varicella-zoster virus, molecular biology, pathogenesis and clinical Aspects. Contrib Microbiol 1999; 3: 158-72
29. McGill J, MacDonald DR, Fall C, et al. Intravenous acyclovir in acute herpes zoster infection. J Infect 1983; 6: 157-61
30. Huff JC, Drucker JL, Clemmer A, et al. Efficacy of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993; Suppl. 1: 93-6
31. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93-5
32. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10: 177-82
33. Colin J, Prisant O, Cochener B, et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000; 107 (8): 1507-11
34. Balfour HH. Antiviral drugs. N Engl J Med 1999; 340: 1255-68
35. Wutzler P, Doerr HW. Antivirale Therapie des Zoster. Dtsch Aerztbl 1998; 95 C: 79-81
36. De Clercq E, Descamps J, De Somer P, et al. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A 1979; 76: 2947-51
37. De Clercq E, Degreef H, Wildiers J, et al. Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine in severe Herpes zoster. BMJ 1980; 281: 1178
38. De Clercq E, Descamps J, Verhelst G, et al. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis 1980; 141: 563-74
39. Heidl M, Scholz H, Doerffel W, et al. Vergleichende Pruefung der Wirksamkeit von Bromvinyldesoxyuridin und Aciclovir bei Varicella-Zoster-Virus-Infektionen immunsupprimierter Kinder: eine prospektive, randomisierte Studie. Z Kiln Med 1990; 45 (14): 1259-62
40. Wutzler P, De Clercq E, Wutke K, et al. Oral brivudin vs intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomised double-blind trial. J Med Virol 1995; 46: 252-7
41. De Clercq E, Descamps J, Balzarini J, et al. Antiviral activity of the 3′amino derivative of (E)-5-(2-bromovinyl)-2′-deoxyuridine. Biochem J 1983; 211: 439-45
42. De Clercq E, Balzarini J, Bernaerts R, et al. Selective antiherpetic activity of carbocyclic analogues of (E)-5-(2-bromovinyl)-2′-deoxyuridines: dependence on specific phosphorylation by viral thymidine kinase. Biochem Biophy Res Commun 1985; 126: 397-403
43. De Clercq E. Towards a selective chemotherapy of virus infections: development of bromovinyldeoxyurinde as a highly potent and selective antiherpetic drug. Verh K Acad Geneeskd Belg 1986; 48: 261-90
44. Wassilew SW. Neues und Bewährtes in der Herpes zoster Therapie. Deutscher Dermatologe 2001; 10: 692-6
45. Wassilew SW, Wutzler. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res. In press
46. Wassilew SW, Stubinski BM, Koch I, et al. Brivudin compared to acyclovir and famciclovir: effect on ZAP [abstract]. Presented at the 14th International Conference on Antiviral Research; 2001 Apr 8-12; Seattle, 180
47. Wutzler P, Wassilew SW, Stubinski BM, et al. Efficacy and safety of brivudin in the treatment of herpes zoster [abstract]. 14th International Conference on Antiviral Research; Seattle: Antiviral Res 2001; 69: 108
48. De Clercq E, Cassiman JJ. Mutagenic potential of anti-herpes agent life. Science 1986; 38: 281-9
49. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues: a survey. Antiviral Res 2001; 49: 55-74
50. World Health Organization. Cancer pain relief. Aufl Genf 1996, 2
51. Zens M, Jurna I. Lehrhuch der Schmerztherapie Wissenschaftliche. Verlagsgesellschaft Stuttgart, 2001